Abstract
Cardiovascular risk factors, irregardless of their assessment modalities, are based on cardiovascular health. Lifestyle influences metabolic profiles and these changes affect cardiovascular risk factors.
Cardiovascular risk factors can be classified into three basic categories: 1. Predisposing risk factors (e.g., age, gender, medical history, and genetic factors); 2. Clinical and metabolic factors (e.g., hypertension, changes in lipid metabolism, diabetes mellitus, obesity, metabolic syndrome, homocysteine, serum uric acid concetntrations, and L-arginine dimethylated derivatives); 3. Modifying behavioral factors (e.g., cigarette smoking, high caloric diet, alcohol intake, sedentary life). Some of these factors are metabolic components of body metabolism because they act by metabolic reactions while others characterized by structural alterations of the cardiovascular system, at least initially, exert their harmful effects by metabolic substrates.
Metabolic responses such as biochemical substances, drugs or others, that act initially as cardiovascular risk factors, identify that an early treatment of the altered parameters observed should be a useful approach to reduce the rate of heart attacks with a significant improvement in the outcome of cardiovascular disease.
Keywords: Cardiovascular risk factor (s), metabolic response, heart and blood vessel rate.
Current Pharmaceutical Design
Title:Modification of Lifestyle Factors are Needed to Improve the Metabolic Health of Patients with Cardiovascular Disease Risk
Volume: 20 Issue: 39
Author(s): Linda Landini
Affiliation:
Keywords: Cardiovascular risk factor (s), metabolic response, heart and blood vessel rate.
Abstract: Cardiovascular risk factors, irregardless of their assessment modalities, are based on cardiovascular health. Lifestyle influences metabolic profiles and these changes affect cardiovascular risk factors.
Cardiovascular risk factors can be classified into three basic categories: 1. Predisposing risk factors (e.g., age, gender, medical history, and genetic factors); 2. Clinical and metabolic factors (e.g., hypertension, changes in lipid metabolism, diabetes mellitus, obesity, metabolic syndrome, homocysteine, serum uric acid concetntrations, and L-arginine dimethylated derivatives); 3. Modifying behavioral factors (e.g., cigarette smoking, high caloric diet, alcohol intake, sedentary life). Some of these factors are metabolic components of body metabolism because they act by metabolic reactions while others characterized by structural alterations of the cardiovascular system, at least initially, exert their harmful effects by metabolic substrates.
Metabolic responses such as biochemical substances, drugs or others, that act initially as cardiovascular risk factors, identify that an early treatment of the altered parameters observed should be a useful approach to reduce the rate of heart attacks with a significant improvement in the outcome of cardiovascular disease.
Export Options
About this article
Cite this article as:
Landini Linda, Modification of Lifestyle Factors are Needed to Improve the Metabolic Health of Patients with Cardiovascular Disease Risk, Current Pharmaceutical Design 2014; 20 (39) . https://dx.doi.org/10.2174/1381612820666140417094458
DOI https://dx.doi.org/10.2174/1381612820666140417094458 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [ Hot Topic: The Blood-Brain Barrier as a Cause of Disease (Executive Editor: William A. Banks) ]
Current Pharmaceutical Design Editorial from Guest Editor (Thematic Issue: Connective Tissue Disease-Associated Interstitial Lung Disease)
Current Respiratory Medicine Reviews Total Bakkenolides Protects Neurons Against Cerebral Ischemic Injury Through Inhibition of Nuclear Factor-κB Activation
CNS & Neurological Disorders - Drug Targets Use of Diverse Chemometric and Validation Methods to Accurately Predict Human Urotensin-II Receptor Antagonist Activity
Current Computer-Aided Drug Design Dynamic Changes in Phenotypic Groups in Patients with Stable Angina Pectoris after Treatment with Xinxuekang Capsule: A Randomized Controlled Trial
Current Vascular Pharmacology Pulmonary Disease in Beta-Thalassemia
Current Respiratory Medicine Reviews Hypertension in Older Patients
Current Hypertension Reviews Serum Creatinine vs. Albuminuria as Biomarkers for the Estimation of Cardiovascular Risk
Current Vascular Pharmacology Current Options for the Pharmacotherapy of Obesity
Current Pharmaceutical Design Crocin Protects Against Beta-Amyloid Peptide-Induced Apoptosis in PC12 Cells Via the PI3 K Pathway
Current Molecular Pharmacology COX-2 Inhibitors and Cardiovascular Events: Deja Vu Du Jour
Vascular Disease Prevention (Discontinued) Fatty Acids: Friends or Foe? Relation Between Dietary Fat and Insulin Sensitivity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) An Efficient and Green Catalytic Method for Friedländer Quinoline Synthesis Using Tungstophosphoric Acid Included in a Polymeric Matrix
Current Catalysis Recent Updates of N-Type Calcium Channel Blockers with Therapeutic Potential for Neuropathic Pain and Stroke
Current Topics in Medicinal Chemistry Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Persistent Clinical Response of Infliximab Therapy in Patients with Refractory Rheumatoid Arthritis, over a 3-Year Period
Current Clinical Pharmacology The Potential Role of Thiamine (Vitamin B1) in Diabetic Complications
Current Diabetes Reviews Silent Cerebral Damage in Hypertension
Current Hypertension Reviews Regulators of G Protein Signaling: Potential Drug Targets for Controlling Cardiovascular and Immune Function
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Beneficial Effects of Statins on Endothelial Dysfunction and Vascular Stiffness
Current Vascular Pharmacology